These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24515100)

  • 1. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings.
    Mahmood I
    Clin Pharmacokinet; 2014 Apr; 53(4):327-46. PubMed ID: 24515100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age.
    Mahmood I
    Ther Drug Monit; 2007 Jun; 29(3):271-8. PubMed ID: 17529882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
    Edginton AN; Shah B; Sevestre M; Momper JD
    Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of drug clearance in children: a review of different methodologies.
    Mahmood I
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):573-87. PubMed ID: 25740388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of drug clearance in children.
    Foissac F; Bouazza N; Valade E; De Sousa Mendes M; Fauchet F; Benaboud S; Hirt D; Tréluyer JM; Urien S
    J Clin Pharmacol; 2015 Jul; 55(7):739-47. PubMed ID: 25721251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical considerations for dose selection in pediatric patients to ensure target exposure requirements.
    Barbour AM; Fossler MJ; Barrett J
    AAPS J; 2014 Jul; 16(4):749-55. PubMed ID: 24841797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of drug clearance in children: an evaluation of the predictive performance of several models.
    Mahmood I; Staschen CM; Goteti K
    AAPS J; 2014 Nov; 16(6):1334-43. PubMed ID: 25274608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages.
    Strougo A; Yassen A; Monnereau C; Danhof M; Freijer J
    J Clin Pharmacol; 2014 Sep; 54(9):1006-15. PubMed ID: 24676942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.
    Mahmood I
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):53-9. PubMed ID: 24519316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
    Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
    JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Björkman S
    Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children ≤2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models.
    Mahmood I
    J Clin Pharmacol; 2016 Jun; 56(6):733-9. PubMed ID: 26437918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
    Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allometry Is a Reasonable Choice in Pediatric Drug Development.
    Liu T; Ghafoori P; Gobburu JV
    J Clin Pharmacol; 2017 Apr; 57(4):469-475. PubMed ID: 27649629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of drug clearance in children 3 months and younger: an allometric approach.
    Mahmood I
    Drug Metabol Drug Interact; 2010; 25(1-4):25-34. PubMed ID: 21417791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults.
    Knibbe CA; Zuideveld KP; Aarts LP; Kuks PF; Danhof M
    Br J Clin Pharmacol; 2005 Jun; 59(6):705-11. PubMed ID: 15948935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
    Calvier EA; Krekels EH; Välitalo PA; Rostami-Hodjegan A; Tibboel D; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2017 Mar; 56(3):273-285. PubMed ID: 27510367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.